|
|
|
| Establishment of an adriamycin resistant human leukemia cell Line U937/ADR and its biological characterizations |
| XUE Fang1|CHENG Zhi-yong2|YANG Lin1LI Shi-hui3|ZHANG Ying1|PAN Ling1 |
| 1 Department of Hematology, the Second Hospital of Hebei Medical University, Shijiazhuang050000, China
2 Department of Hematology, the First Hospital of Baoding, Baoding071000, China
3 Department of Oncology, the Center Hospital of Aviation lndustry of Beijing| Beijing100012|China
|
|
|
|
Abstract Abstract Objective：To establish a human multi-drug resistant leukemia cell line U937/ADR and investigate its biological characterization. Methods：Adriamycin resistant leukemia cell line U937/ADR was produced by high dose and short term methods; The cell growth and resistant index was tested by MTT; The cell cycle was detected by flow cytometry (FCM); Drug excretion was tested by rhodamine123 (Rho123); MDR1, MRP1, NF-Κb, Bcl-2, Bax mRNA were detected by real-time fluorescent relative-quantification reverse transcriptional PCR (FQ-PCR); P-gp, MRP1, Akt, p-Akt and p65 protein levels were detected by Western blot. Results: Drug resistant cell line U937/ADR was successfully established and the ADR resistant index was 11 fold than U937 cells. The doubling time of U937/ADR cells were 43.6h and longer than that of U937 cells. Cell cycle showed that the G0/G1 phase cells increased and G2/M phase cells decreased in U937/ADR cells and it showed the cross resistant to many drugs and drug excretion increased. MDR1, NF-Κb, Bcl-2 mRNA and P-gp, P65, Bcl-2 and p-Akt protein increased in U937/ADR cells. Conclusion： The biological characterizations of U937/ADR were different to those of U937, which showed the cross resistant to many drugs and over-expression of the P-gp, activated NF-Kb and p-Akt.
|
|
Received: 19 November 2008
Published: 28 July 2009
|
|
|
|
|
| ［1］ 杨纯正. 肿瘤耐药研究的若干问题. 中华医学杂志，2001,81(24)：1475~1478
Yang C Z. National Medical Journal of China，2001, 81(24)：1475~1478
［2］ Grandage V L, Gale R E, Linch D C,et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia，2005,19(4):586~594
［3］ Sood A K, Buller R E. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol, 1998, 92(2): 312~319
［4］ Yang L Y, Trujillo J M. Biological characterization of multidrμg resistant human colon carcinoma sublines induced by two methods. Cancer Res, 1990, 50(2): 3218~3336
［5］ Uchiyama-kokubu N, Walanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs, 2001, 12(9): 769~777
［6］ 杨纯正. 肿瘤耐药研究进展. 中华血液学杂志, 1997, 18(1): 1~2
Yang C Z. Chinese Journal of Hematology, 1997, 18(1): 1~2
［7］ Tran T T, Mittal A, Aldinger T, et al. The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J, 2005, 88(1): 715~738
［8］ Meaden E R, Hoggard P G, Khoo S H, et al. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods, 2002, 262(1-2): 159~165
［9］ 顾静文. 急性白血病患者P-gp、mdr1、MRP和TopoⅡ表达及其与预后关系的研究. 中华血液学杂志，2001, 22(2): 90~93
Gu J W. Chinese Journal of Hematology, 2001, 22(2): 90~93
［10］ Karakas Z, Agaoglu L, Erdem S, et al. Prognostic value of P-gp expression and related function in childhood acute leukemia. Adv Exp Med Biol, 1999, 457 (1): 21~28
［11］ 朴瑛, 陈协群, 刘丽梅等. bcl-2小干扰RNA对HL-60/VCR细胞耐药性逆转的研究. 中国实验血液学杂志, 2005, 13(6): 1010~1015
Piao Y, Chen X Q, Liu L M, et al. Journal of Experimental Hematology, 2005, 13(6): 1010~1015
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
